HBM Healthcare Investments AG

  • ISIN: CH0012627250
  • Land: Schweiz

Alle Mitteilungen

EQS-News 16.11.21 17:46 EQS-News: HBM Healthcare Investments AG
Key Figures 15.11.2021
EQS-News 08.11.21 06:46 EQS-News: HBM Healthcare Investments AG
HBM Healthcare Investments profitiert vom Börsengang des Portf[...]
EQS-News 02.11.21 17:46 EQS-News: HBM Healthcare Investments AG
Key Figures 31.10.2021
EQS-Ad-hoc 22.10.21 06:45 EQS-Ad-hoc: HBM Healthcare Investments AG
HBM Healthcare Investments Halbjahresbericht September 2021
EQS-News 18.10.21 17:46 EQS-News: HBM Healthcare Investments AG
Key Figures 15.10.2021
EQS-News 01.10.21 17:47 EQS-News: HBM Healthcare Investments AG
Key Figures 30.09.2021
EQS-Ad-hoc 01.10.21 17:46 EQS-Ad-hoc: HBM Healthcare Investments AG
HBM Healthcare Investments erzielt Wertsteigerung von 12.6 Pro[...]
EQS-News 16.09.21 17:47 EQS-News: HBM Healthcare Investments AG
Key Figures 15.09.2021
EQS-News 01.09.21 17:47 EQS-News: HBM Healthcare Investments AG
Key Figures 31.08.2021
EQS-News 16.08.21 17:58 EQS-News: HBM Healthcare Investments AG
Key Figures 15.08.2021
EQS-News 02.08.21 17:46 EQS-News: HBM Healthcare Investments AG
Key Figures 31.07.2021
EQS-Ad-hoc 23.07.21 06:46 EQS-Ad-hoc: HBM Healthcare Investments AG
HBM Healthcare Investments Quartalsbericht Juni 2021
EQS-News 16.07.21 18:08 EQS-News: HBM Healthcare Investments AG
Key Figures 15.07.2021
EQS-News 01.07.21 18:40 EQS-News: HBM Healthcare Investments AG
Key Figures 30.06.2021
EQS-Ad-hoc 25.06.21 06:45 EQS-Ad-hoc: HBM Healthcare Investments AG
Erfolgreicher Börsengang für das HBM-Portfoliounter-nehmen Mon[...]
EQS-Ad-hoc 21.06.21 06:45 EQS-Ad-hoc: HBM Healthcare Investments AG
HBM Portfoliounternehmen Ambrx Biopharma nimmt bei Börsengang [...]
EQS-Ad-hoc 18.06.21 17:45 EQS-Ad-hoc: HBM Healthcare Investments AG
Generalversammlung der HBM Healthcare Investments stimmt allen[...]
EQS-Ad-hoc 16.06.21 18:00 EQS-Ad-hoc: HBM Healthcare Investments AG
HBM Healthcare Investments hat die Zeichnungsfrist für die Anl[...]
EQS-News 16.06.21 17:45 EQS-News: HBM Healthcare Investments AG
Key Figures 15.06.2021
EQS-Ad-hoc 15.06.21 07:00 EQS-Ad-hoc: HBM Healthcare Investments AG
HBM Healthcare Investments AG begibt eine Anleihe über mindest[...]

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021